The Growing Burden of Allergic Rhinitis in India
Rapid urbanization, seasonal pollen dispersion, and high particulate pollution levels have led to a sharp increase in respiratory allergies. Patients frequently present with debilitating sneezing, rhinorrhea, nasal congestion, ocular itching, and secondary bronchial hyperresponsiveness.
The Power of Dual Pathway Inhibition
Monotherapy with simple antihistamines often fails to alleviate nasal congestion caused by cysteinyl leukotrienes. Combining a potent second-generation antihistamine with a leukotriene receptor antagonist delivers complete symptom relief:
- Levocetirizine (5mg): Rapidly blocks peripheral H1 histamine receptors to halt acute allergic responses (sneezing, runny nose, watery eyes) without causing excessive sedation.
- Montelukast Sodium (10mg): Selectively antagonizes the CysLT1 receptor, inhibiting leukotriene-mediated airway smooth muscle contraction, microvascular permeability, and mucosal edema.
Clinical Indications for SHIKMONT-DL
- Seasonal and Perennial Allergic Rhinitis.
- Allergic Bronchial Asthma associated with rhinitis symptoms.
- Chronic Idiopathic Urticaria and allergic skin dermatoses.
- Post-viral allergic dry cough and nocturnal wheezing.
For dosage schedules, packaging specifications, and franchise inquiries for SHIKMONT-DL Tablets, contact our regional distribution team today.